The most commonly reported side effects of deuruxolitinib include product dose omission issue, therapy cessation, and off label use, based on 12 FDA adverse event reports from 2025 to 2025. 8.3% of reports found the drug to be ineffective.
Percentages show how often each reaction appears relative to total reports for deuruxolitinib.
These are voluntary reports and do not establish that deuruxolitinib caused these reactions.
Report severity
Seriousness is determined by the reporter, not by OpenClaim.
Other drugs that appear in adverse event reports alongside deuruxolitinib. Drugs flagged as a suspected cause appear in the first column. Drugs taken at the same time but not suspected appear in the second.
Taken alongside
Co-occurrence in adverse event reports does not establish a drug interaction. Patients often take multiple medications, and these lists reflect prescribing patterns rather than causal relationships. Consult a healthcare provider about potential drug interactions.
41.7% of deuruxolitinib adverse event reports involve female patients and 25.0% involve male patients. The largest age group is adult at 83%. These figures reflect who reports side effects, not underlying risk.
Sex
Age group
Conditions and purposes for which patients were taking deuruxolitinib when the adverse event was reported.
Ask OpenClaim about your specific drug combination. Get a sourced report using FDA data, drug labels, and medical literature.